Exabis Library
Welcome to the e-CCO Library!
DOP088: Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controls
2016
ECCO'16 DOP
1
DOP088: Microbial dysbiosis increases experimental colitis by interfering with short-chain fatty acid dependent mucosal Reg3B expression
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP088: Somatic and visceral hypersensitivity associated to acute intestinal inflammation are absent in sigma 1 receptor knockout mice
2017
ECCO'17 Barcelona
1
DOP089: Microbiota profiles in treatment naïve Norwegian IBD and non-IBD patients. Part of the EU IBD character consortium
2016
ECCO'16 DOP
1
DOP089: PTPN2 controls intestinal inflammation and promotes Colitis-associated tumour formation via control of inflammasome activation and IL-1alpha release
2017
ECCO'17 Barcelona
1
DOP08: Deep remission in paediatric Crohn’s Disease is associated with increased abundance of Dialister species and increased valerate
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP08: The regulatory landscape of intestinal cells – investigating the transcriptional effect of autophagy impairment observed in Crohn’s disease using organoid and network biology approaches
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP090: Risk factors for bacteremia in hospitalized patients with Inflammatory Bowel Disease
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP090: The Role of The Microbiome in Clinical Response to Golimumab in Ulcerative Colitis
2016
ECCO'16 DOP
1
DOP090: The α7 nicotinic acetylcholine receptor agonist GTS-21 attenuate DSS-induced Colitis by improving intestinal mucosal barrier function
2017
ECCO'17 Barcelona
1
DOP10: Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial substudy
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP10: Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP11: Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP13: Immune profiling of adipose tissue in murine models of Inflammatory Bowel Disease (IBD)
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP15: Metabolomics coupled with pathway analysis characterize metabolic changes in treatment-naive Ulcerative Colitis patients
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP15: Transmural healing with vedolizumab in patients with active Crohn’s Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP16: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1